Morgan Stanley raised the firm’s price target on Humana (HUM) to $301 from $288 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Lawmakers seek to break up PBMs from health insurers, WSJ reports
- CEO killing, rage over insurance pushes UnitedHealth into crisis, Bloomberg says
- AT&T announces long-term targets, BlackRock acquires HPS: Morning Buzz
- Humana (HUM) Stock Falls on News of CFO Departure
- Insurers collected billions in premiums from Medicare for veterans, WSJ says